HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Abequolixron

HCID 10218693
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
610318-54-2
Standard SMILES
C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1
InChIKey
ZLJZDYOBXVOTSA-XMMPIXPASA-N
Molecular formula
C34H33ClF3NO3
Average molar mass
596.1 g/mol
Monoisotopic mass
595.2101061

Overview

Abequolixron is an orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.

Names & identifiers

Preferred name
Abequolixron
IUPAC
2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid
English name
RGX-104 free Acid
Molecular formula
C34H33ClF3NO3
Molecular weight
596.08

Names & synonyms

610318-54-2AbequolixronSB-742881Q26B92650VRGX104Benzeneacetic acid, 3-((3R)-3-(((2-chloro-3-(trifluoromethyl)phenyl)methyl)(2,2-diphenylethyl)amino)butoxy)-2-(3-((3R)-3-(((2-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)METHYL)(2,2-DIPHENYLETHYL)AMINO)BUTOXY)PHENYL)ACETIC ACIDBenzeneacetic acid, 3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]butoxy]-RefChem:1075138LXR-b Agonist RGX-104RGX 104Liver X Receptor beta Agonist RGX-104
Show more names
RGX-104 (free form)RGX-104, 10 mM in DMSOAbequolixron (RGX-104)RGX-104freeAcid/SB742881610318-54-2 (FREE FORM) 610318-03-1 (HCL)RGX 104,inhibit,LXR,RGX-104,Liver X receptor,RGX104,Inhibitor(R)-2-(3-(3-((2-Chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)butoxy)phenyl)acetic acid
(3-((3r)-3-(((2-chloro-3-(trifluoromethyl)phenyl)methyl)(2,2-diphenylethyl)amino)butoxy)phenyl)acetic acidRGX-104 free AcidRGX-104Abequolixron [USAN]RGX104 Free AcidRGX-104 free formSB742881RGX-104 free Acid?

Properties

Computed structural propertiesFilling in

XLogP
6.3
Topological polar surface area
49.8 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
7
Rotatable bonds
13
Heavy atoms
42
Formal charge
0
Complexity
783

Physicochemical properties

Boiling point
677.1 · 677.1±55.0 °C(Predicted)
Density
1.246 · 1.246±0.06 g/cm3(Predicted)
storage temp.
4 °C, · 4°C, protect from light
solubility
100 · DMSO:100.0(Max Conc. mg/mL);167.76(Max Conc. mM)
pka
4.19 · 4.19±0.10(Predicted)
form
Solid
color
White to off-white
InChIKey
ZLJZDYOBXVOTSA-XMMPIXPASA-N
SMILES
C1(CC(O)=O)=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C2=CC=CC=C2)C2=CC=CC=C2)C)=C1
FDA UNII
26 B92650V · Q26B92650V
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P305+P351+P338

Chemistry & industry

Applications

UsesRGX-104 is combination of a liver X receptor β agonist and GITR modulator for treatment of cancer.Liver X receptor beta agonist.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
610318-54-2
PubChem CID
10218693
ChEMBL
CHEMBL573677
UNII
Q26B92650V